Reactome | Cinaciguat binds sGC:NO

Cinaciguat binds sGC:NO

Stable Identifier

R-HSA-9621179

Type

Reaction [binding]

Species

Homo sapiens

Compartment

cytosol

ReviewStatus

5/5

Locations in the PathwayBrowser

Expand all

General

SBML | | PDF

SVG | | PPTX | SBGN

Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Soluble guanylate cyclase (sGC) modulators are small-molecule drugs that bind sGC and enhance nitric oxide (NO)-mediated cGMP signalling. The suffix “ciguat” is the unique identifier for this drug class. There are two types of "ciguats"; NOsGC stimulators, which act through allosteric regulation and NOsGC activators, which occupy the heme binding site and work additively with NO (Kraehling & Sessa 2017).

In the early 2000s, cinaciguat (BAY 58-2667) was identified as a novel NOsGC activator (Stasch et al. 2002). Cinaciguat has been shown to unload the heart in patients with acute decompensated heart failure (ADHF). However, high doses of cinaciguat are associated with hypotension (Erdmann et al. 2013).

Literature References

PubMed ID	Title	Journal	Year
22778174	Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure Mebazaa, A, Nieminen, MS, Semigran, MJ, Mitrovic, V, Agrawal, R, Gheorghiade, M, Erdmann, E	Eur. Heart J.	2013